Tirzepatide is associated with similar odds for gastrointestinal adverse events and a lower likelihood for diabetic retinopathy and pancreatitis compared with GLP-1 receptor agonists, according to a presenter.
“Our analysis of the FDA Adverse Events Reporting System database suggests that, despite its unprecedented glucose and weight lowering efficacy, tirzepatide has a similar, if not better, safety profile compared to the already widely used GLP-1 receptor agonists in terms of gastrointestinal adverse events, pancreatobiliary disorders, diabetic retinopathy and medullary thyroid cancer,”